AZD4205

DRUG4 trials

Sponsors

Dizal Pharmaceuticals

Conditions

Healthy VolunteersNonsmall Cell Lung CancerPeripheral T Cell LymphomaPeripheral T-cell Lymphoma

Phase 1

Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer

CompletedNCT03450330

Dizal PharmaceuticalsNonsmall Cell Lung Cancer

Start: 2018-04-16End: 2020-01-10Updated: 2020-08-24

A Study of AZD4205 in Healthy Adult Subjects

CompletedNCT03728023

Dizal PharmaceuticalsHealthy Volunteers

Start: 2018-11-12End: 2019-08-20Updated: 2020-08-24

Phase 2

AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

CompletedNCT06511869

Dizal PharmaceuticalsPeripheral T-cell Lymphoma

Start: 2022-03-17End: 2025-03-31Updated: 2025-07-04

AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

CompletedNCT06511895

Dizal PharmaceuticalsPeripheral T Cell Lymphoma

Start: 2022-05-31End: 2025-10-17Updated: 2025-12-24

Related Papers

Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)

Blood Cancer Journal2026-03-17

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Blood2024-11-05

Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants

Frontiers in Immunology2023-04-036 citations

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.

2021-11-1315 citations

17 AZD4205, A SELECTIVE, GI TRACT-ENRICHED SELECTIVE JAK1 INHIBITOR FOR CROHN’S DISEASE: PRECLINICAL EVIDENCE AND PHASE I DATA

Inflammatory Bowel Diseases2020-01-01

DOP17 AZD4205, a potent, GI tract-enriched, JAK1-selective inhibitor for treatment of inflammatory bowel disease (IBD)

Journal of Crohn s and Colitis2019-01-251 citations